Press release Biocartis Group NV

Four Abstracts Showing Excellent Data for Idylla Presented at European Society of Molecular Oncology Congress (ESMO)

PRESS RELEASE 20 October 2023, 07:00 CEST

Four Abstracts Showing Excellent Data for Idylla Presented at European Society of Molecular Oncology Congress (ESMO)

Mechelen, Belgium, 20 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces that four study abstracts on Idylla have been selected for poster presentations at the international ESMO (European Society of Molecular Oncology) congress, taking place between 20-24 October 2023 in Madrid (Spain). The studies show excellent data for the Idylla GeneFusion Assay and Idylla EGFR Mutation Assay.

Three studies demonstrate that the Idylla GeneFusion and EGFR Mutation Assays offer a rapid, sensitive and specific method for lung sample profiling in routine practice.

• The first study¹ prospectively tested lung cancer samples on the Idylla Platform as part of routine² lung profiling locally and from over 60 UK hospitals. The investigators tested over 5,000 cases and demonstrated that the Idylla GeneFusion Assay had the expected rate of positivity and a low failure rate. Moreover, the Assay allowed testing to be successfully completed in samples unsuitable for NGS due to low tumor burden.
• The second abstract³ presents the results of a multicenter study that was conducted in a routine clinical² setting involving 12 clinical centers across Europe. Providing high sensitivity and specificity values for all biomarkers, together with a low failure rate and rapid turnaround time (within 3 hours), the investigators concluded that the Idylla GeneFusion Assay technology has emerged as a highly relevant, time efficient and upfront screening tool on FFPE samples.
• The third abstract⁴ presents the results of the ORIGEN study, a multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain (in collaboration with AstraZeneca Spain). The investigators demonstrated a 15% frequency of EGFR mutations, with the most frequent being exon 19 deletions and the presence of the L858R mutation, which is in line with other data reported in Spain in advanced NSCLC. These results reinforce the importance of performing EGFR testing in early-stage NSCLC to predict the most appropriate treatment options.